Takeda, Tsuyoshi
Sasaki, Takashi http://orcid.org/0000-0001-7109-9835
Suzumori, Chisaki
Mie, Takafumi
Furukawa, Takaaki
Yamada, Yuto
Kasuga, Akiyoshi
Matsuyama, Masato
Ozaka, Masato
Sasahira, Naoki
Article History
Received: 29 January 2021
Accepted: 24 March 2021
First Online: 31 March 2021
Declarations
:
: All authors declare no conflicts of interests for this article. Conflicts of interests outside this work are as follows; Naoki Sasahira received research funding from Zeria, Eisai, Kyowa Hakko Kirin, Baxalta and Taiho Pharmaceutical. Masato Ozaka received honoraria from Taiho Pharmaceutical, Yakult, Bayer, Pfizer, Novartis, Takeda Pharmaceutical Company Limited, Eisai, EA pharma and Mitsubishi Tanabe Pharma Corporation and research funding from Merck & Co., Inc., Incyte, ASLAN Pharmaceuticals, Taiho Pharmaceutical and Yakult. Takashi Sasaki received honoraria from Taiho Pharmaceutical and Eisai.
: This study was approved by the ethics committee of our institution (Institutional Review Board number: 2020-1210).